Details
Stereochemistry | ACHIRAL |
Molecular Formula | C47H48N3O7S2.Na |
Molecular Weight | 854.02 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C3C=CC(C=C3C)=[N+](CC)CC4=CC=CC(=C4)S([O-])(=O)=O)C5=C(C)C=C(C=C5)N(CC)CC6=CC=CC(=C6)S([O-])(=O)=O)C=C1
InChI
InChIKey=RWVGQQGBQSJDQV-UHFFFAOYSA-M
InChI=1S/C47H49N3O7S2.Na/c1-6-49(31-35-11-9-13-43(29-35)58(51,52)53)40-21-25-45(33(4)27-40)47(37-15-17-38(18-16-37)48-39-19-23-42(24-20-39)57-8-3)46-26-22-41(28-34(46)5)50(7-2)32-36-12-10-14-44(30-36)59(54,55)56;/h9-30H,6-8,31-32H2,1-5H3,(H2,51,52,53,54,55,56);/q;+1/p-1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18653608Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2610693 | https://www.ncbi.nlm.nih.gov/pubmed/10860929
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18653608
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2610693 | https://www.ncbi.nlm.nih.gov/pubmed/10860929
Brilliant Blue G is triphenylmethane dye that was developed for use in the textile industry but is now commonly used for staining proteins in analytical biochemistry. The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue G to quantify the amount of protein in a solution. Brilliant Blue G also acts as a selective inhibitor of the P2X purinoceptor channel P2X7 (IC50s = 10.1 and 265 nM for rat and human P2X7, respectively). In mice, it inhibits interleukin-1β expression and reduces neurological injury secondary to traumatic brain injury. Brilliant Blue G was used to prepare the protein reagent for the determination of protein content of the collagenase enzyme isolated from fish waste. It may be employed as a stain for the internal limiting membrane (ILM) for the macular hole (MH) and epiretinal membrane (ERM) surgery.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900736 |
265.0 nM [IC50] | ||
Target ID: CHEMBL2104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10860929 |
3160.0 nM [IC50] | ||
Target ID: CHEMBL2531 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10860929 |
1370.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient | Unknown Approved UseUnknown |
|||
Inactive ingredient | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24510005
After removal of posterior hyaloid, 0.2 mL Brilliant Blue G was applied on the macula, to stain epiretinal membraneunder air conditions for 2 minutes.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10860929
Whole-cell recordings were made 20 to 48 h after transient transfection and 24 to 72 h after passage of stable cells, using an EPC9 patch clamp amplifier (HEKA Elektronik, Lambrechet, Germany). Unless otherwise noted, membrane potential was held at 260 mV. Recording pipettes (4–7 MV) were pulled from borosilicate glass (World Precision Instruments, Sarasota, FL) and filled with an intracellular solution that consisted of (in mM): 145 NaF, 10 EGTA, 10 HEPES. The external solution contained (in mM): 147 NaCl, 10 HEPES, 13 glucose, 2 KCl, 2 CaCl2, and 1 MgCl2. Osmolarity and pH values of both solutions were 300 to 315 mOsm/l and 7.3, respectively. All the experiments presented here were performed at room temperature. Agonists and Brilliant Blue G were applied using an RSC 200 fast-flow delivery system (Biologic Science Instruments, Grenoble, France). Agonists were applied every 2 min except for experiments on P2X1, P2X3, and rat P2X4, in which 3- to 8-min intervals were used because of the prolonged rundown of these responses. The duration of agonist application was 1 s for the P2X1 receptor, 2 s for the P2X2, P2X3, and P2X2/3, and P2X4 receptors, 3 s for the P2X1/5 receptor, and 4 s for the P2X7 receptor. For all except the P2X1 receptor, repetitive stimuli at the frequencies noted above were applied in the absence of Brilliant Blue G until evoked currents were stable (65%); the clamped cell was perfused with Brilliant Blue G (0.1–10 mM) for 4 min, and current evoked by agonist was measured. The peak current amplitude was expressed as a percentage of the amplitude obtained under the control conditions. Because of the marked rundown of currents at the P2X1 receptor, Brilliant Blue G was added to the cells for 4 min after the second application of agonist. The ratios of the peak amplitude induced by the third application of agonist relative to the peak amplitude by the second application of agonist were calculated and compared in the absence and presence of Brilliant Blue G.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
257908
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
||
|
FDA ORPHAN DRUG |
876222
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
||
|
FDA ORPHAN DRUG |
341811
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000036121
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
328382
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
61363
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
m11949
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
M1ZRX790SI
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
DTXSID7041706
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
6104-58-1
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
DB15594
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
1998867
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
M1ZRX790SI
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY | |||
|
5359
Created by
admin on Fri Dec 15 18:56:06 UTC 2023 , Edited by admin on Fri Dec 15 18:56:06 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD